The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
lead nitrate inhibits the reaction [2-amino-3-methyl-9H-pyrido(2,3-b)indole results in increased expression of CYP1A1 mRNA]; lead nitrate inhibits the reaction [2-amino-3-methyl-9H-pyrido(2,3-b)indole results in increased expression of CYP1A1 protein] 2-amino-3-methyl-9H-pyrido(2,3-b)indole results in increased expression of CYP1A1 mRNA; 2-amino-3-methyl-9H-pyrido(2,3-b)indole results in increased expression of CYP1A1 protein
2-amino-3-methyl-9H-pyrido(2,3-b)indole results in increased expression of CYP1A2 mRNA; 2-amino-3-methyl-9H-pyrido(2,3-b)indole results in increased expression of CYP1A2 protein lead nitrate inhibits the reaction [2-amino-3-methyl-9H-pyrido(2,3-b)indole results in increased expression of CYP1A2 mRNA]; lead nitrate inhibits the reaction [2-amino-3-methyl-9H-pyrido(2,3-b)indole results in increased expression of CYP1A2 protein] CYP1A2 protein results in increased activity of and results in increased hydroxylation of 2-amino-3-methyl-9H-pyrido(2,3-b)indole; CYP1A2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-3-methyl-9H-pyrido(2,3-b)indole
NAT2 protein results in increased activity of 2-amino-3-methyl-9H-pyrido(2,3-b)indole NAT2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-3-methyl-9H-pyrido(2,3-b)indole
2-amino-3-methyl-9H-pyrido(2,3-b)indole inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] 2-amino-3-methyl-9H-pyrido(2,3-b)indole results in decreased activity of SLC22A2 protein
SULT1A1 protein results in increased activity of and results in increased sulfation of 2-amino-3-methyl-9H-pyrido(2,3-b)indole; SULT1A1 protein results in increased metabolism of and results in increased susceptibility to 2-amino-3-methyl-9H-pyrido(2,3-b)indole
CYP1A1 protein results in increased metabolism of and results in increased activity of 2-amino-9H-pyrido(2,3-b)indole 2-amino-9H-pyrido(2,3-b)indole results in increased expression of CYP1A1 mRNA
CYP1A2 protein results in increased metabolism of and results in increased activity of 2-amino-9H-pyrido(2,3-b)indole 2-amino-9H-pyrido(2,3-b)indole results in increased expression of CYP1A2 mRNA [CYP1A2 protein co-treated with NAT2 gene polymorphism] promotes the reaction [2-amino-9H-pyrido(2,3-b)indole binds to and results in increased mutagenesis of HPRT1 gene]; [furafylline results in decreased activity of CYP1A2 protein] which results in decreased susceptibility to 2-amino-9H-pyrido(2,3-b)indole; CYP1A2 protein results in increased metabolism of and results in increased activity of 2-amino-9H-pyrido(2,3-b)indole; CYP1A2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-9H-pyrido(2,3-b)indole
[CYP1A2 protein co-treated with NAT2 gene polymorphism] promotes the reaction [2-amino-9H-pyrido(2,3-b)indole binds to and results in increased mutagenesis of HPRT1 gene]
[CYP1A2 protein co-treated with NAT2 gene polymorphism] promotes the reaction [2-amino-9H-pyrido(2,3-b)indole binds to and results in increased mutagenesis of HPRT1 gene]; NAT2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-9H-pyrido(2,3-b)indole NAT2 gene polymorphism affects the susceptibility to 2-amino-9H-pyrido(2,3-b)indole
2-amino-9H-pyrido(2,3-b)indole inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] 2-amino-9H-pyrido(2,3-b)indole results in decreased activity of SLC22A2 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine promotes the reaction [2-amino-9H-pyrido(2,3-b)indole inhibits the reaction [SLC22A8 protein results in increased import of 6-carboxyfluorescein]]; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine promotes the reaction [2-amino-9H-pyrido(2,3-b)indole results in decreased activity of SLC22A8 protein]; 2-amino-9H-pyrido(2,3-b)indole inhibits the reaction [SLC22A8 protein results in increased import of 6-carboxyfluorescein]; 2-amino-9H-pyrido(2,3-b)indole promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [SLC22A8 protein results in increased import of 6-carboxyfluorescein]]; 2-amino-9H-pyrido(2,3-b)indole promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased activity of SLC22A8 protein]
CYP1A2 protein affects the metabolism of 3-amino-1-methyl-5H-pyrido(4,3-b)indole 3-amino-1-methyl-5H-pyrido(4,3-b)indole results in increased expression of CYP1A2 mRNA CYP1A2 protein results in increased metabolism of and results in increased susceptibility to 3-amino-1-methyl-5H-pyrido(4,3-b)indole 3-amino-1-methyl-5H-pyrido(4,3-b)indole results in increased activity of CYP1A2 protein CYP1A2 protein affects the susceptibility to 3-amino-1-methyl-5H-pyrido(4,3-b)indole
3-amino-1-methyl-5H-pyrido(4,3-b)indole results in decreased activity of POR protein 3-amino-1-methyl-5H-pyrido(4,3-b)indole promotes the reaction [purpurin results in increased activity of POR protein]
3-amino-1-methyl-5H-pyrido(4,3-b)indole inhibits the reaction [SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]; 3-amino-1-methyl-5H-pyrido(4,3-b)indole inhibits the reaction [SLC22A1 protein results in increased import of Tetraethylammonium] 3-amino-1-methyl-5H-pyrido(4,3-b)indole results in decreased activity of SLC22A1 protein
3-amino-1-methyl-5H-pyrido(4,3-b)indole inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]; 3-amino-1-methyl-5H-pyrido(4,3-b)indole inhibits the reaction [SLC22A2 protein results in increased import of Tetraethylammonium] 3-amino-1-methyl-5H-pyrido(4,3-b)indole results in decreased activity of SLC22A2 protein
3-amino-1-methyl-5H-pyrido(4,3-b)indole results in decreased activity of SLC22A3 protein 3-amino-1-methyl-5H-pyrido(4,3-b)indole inhibits the reaction [SLC22A3 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]
3-amino-1-methyl-5H-pyrido(4,3-b)indole results in decreased activity of SLC22A8 protein 3-amino-1-methyl-5H-pyrido(4,3-b)indole inhibits the reaction [SLC22A8 protein results in increased import of 6-carboxyfluorescein]
norharman inhibits the reaction [Lipids metabolite results in increased activity of AHR protein] norharman results in increased activity of AHR protein
CYP1A1 protein affects the metabolism of [norharman co-treated with aniline] norharman results in increased expression of CYP1A1 mRNA; norharman results in increased expression of CYP1A1 protein
norharman inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] norharman results in decreased activity of MAOB protein
norharman inhibits the reaction [SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] norharman results in decreased activity of SLC22A1 protein
norharman inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] norharman results in decreased activity of SLC22A2 protein
norharman results in decreased activity of SLC22A3 protein norharman inhibits the reaction [SLC22A3 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]
evodiamine results in decreased phosphorylation of AKT1 protein evodiamine inhibits the reaction [TNF protein results in increased activity of AKT1 protein]; wortmannin promotes the reaction [evodiamine results in decreased phosphorylation of AKT1 protein] evodiamine inhibits the reaction [INS1 results in increased phosphorylation of AKT1 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [evodiamine results in increased cleavage of BCL2 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BCL2 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [evodiamine results in increased activity of and results in increased cleavage of CASP3 protein]; EUK-134 inhibits the reaction [evodiamine results in increased cleavage of CASP3 protein]; evodiamine results in increased activity of and results in increased cleavage of CASP3 protein; Rotenone inhibits the reaction [evodiamine results in increased cleavage of CASP3 protein]
evodiamine results in increased phosphorylation of DNM1L protein Rotenone inhibits the reaction [evodiamine results in increased phosphorylation of DNM1L protein]
EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]; EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]; EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of PLCG1 protein]; EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of PRKCA protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of EGFR protein]
evodiamine results in decreased expression of EIF2AK3 protein EUK-134 inhibits the reaction [evodiamine results in decreased expression of EIF2AK3 protein]
evodiamine results in increased expression of FASLG protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [evodiamine results in increased expression of FASLG protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [evodiamine results in increased expression of FASLG protein]; wortmannin inhibits the reaction [evodiamine results in increased expression of FASLG protein]
evodiamine inhibits the reaction [IL1B protein results in increased activity of NFKB1 protein]; evodiamine inhibits the reaction [IL1B protein results in increased activity of RELA protein]
chelerythrine inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]; EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]
chelerythrine inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]; EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [evodiamine results in increased expression of MAPK8 protein modified form]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [evodiamine results in increased expression of MAPK9 protein modified form]
evodiamine inhibits the reaction [Hydrogen Peroxide results in increased activity of NFKB1 protein]; evodiamine inhibits the reaction [IL1B protein results in increased activity of NFKB1 protein]; evodiamine inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein]; evodiamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of NFKB1 protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; evodiamine inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [evodiamine results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; evodiamine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; evodiamine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; evodiamine results in increased phosphorylation of and results in increased degradation of NFKBIA protein; wortmannin inhibits the reaction [evodiamine results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
EUK-134 inhibits the reaction [evodiamine results in increased cleavage of PARP1 protein]; evodiamine promotes the reaction [TNF protein results in increased cleavage of PARP1 protein]; Rotenone inhibits the reaction [evodiamine results in increased cleavage of PARP1 protein]
evodiamine results in increased phosphorylation of PRKCA protein EGFR mutant form inhibits the reaction [evodiamine results in increased phosphorylation of PRKCA protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of PRKCA protein]
evodiamine inhibits the reaction [Hydrogen Peroxide results in increased activity of RELA protein]; evodiamine inhibits the reaction [IL1B protein results in increased activity of RELA protein]; evodiamine inhibits the reaction [Okadaic Acid results in increased activity of RELA protein]; evodiamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of RELA protein]; evodiamine inhibits the reaction [TNF protein affects the localization of RELA protein]; evodiamine inhibits the reaction [TNF protein results in increased acetylation of RELA protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; evodiamine inhibits the reaction [TNF protein results in increased activity of RELA protein]
evodiamine inhibits the reaction [TNF protein affects the localization of RELA protein]; evodiamine inhibits the reaction [TNF protein results in increased acetylation of RELA protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; evodiamine inhibits the reaction [TNF protein results in increased activity of AKT1 protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of CHUK protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of IKBKB protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; evodiamine inhibits the reaction [TNF protein results in increased activity of RELA protein]; evodiamine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of ABCB1 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of CFLAR protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of MYC protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; evodiamine inhibits the reaction [TNF protein results in increased expression of XIAP protein]; evodiamine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; evodiamine promotes the reaction [TNF protein results in increased cleavage of PARP1 protein]
[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein]; Harmaline inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; Harmaline inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of CYP1A1 protein]; Harmaline inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] Harmaline results in decreased activity of CYP1A1 protein Harmaline results in decreased stability of CYP1A1 protein
Harmaline inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Harmaline inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]
Harmaline inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Harmaline inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of NFKB1 protein]
Harmaline inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Harmaline inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of RELA protein]
harmalol results in decreased stability of CYP1A1 protein harmalol results in decreased activity of CYP1A1 protein [Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein]; harmalol inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; harmalol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of CYP1A1 protein]; harmalol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
AHR mutant form inhibits the reaction [harman results in increased activity of CYP1A1 protein]; AHR mutant form inhibits the reaction [harman results in increased expression of CYP1A1 protein]
AHR mutant form inhibits the reaction [harman results in increased activity of CYP1A1 protein]; AHR mutant form inhibits the reaction [harman results in increased expression of CYP1A1 protein]; Dactinomycin inhibits the reaction [harman results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [harman results in increased activity of CYP1A1 protein] harman results in increased expression of CYP1A1 mRNA; harman results in increased expression of CYP1A1 protein
harman results in decreased activity of SLC22A1 protein harman inhibits the reaction [SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]
harman results in decreased activity of SLC22A2 protein harman inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]
harman results in increased activity of TAAR1 protein [harman results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
AZD 6244 inhibits the reaction [Harmine results in increased phosphorylation of CHD4 protein]; Harmine inhibits the reaction [CHD4 protein affects the expression of UCP1 mRNA]; Harmine inhibits the reaction [CHD4 protein binds to UCP1 promoter]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Harmine results in decreased stability of CYP1A1 protein]; Harmine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Harmine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Harmine results in decreased activity of CYP1A1 protein
Harmine inhibits the reaction [DYRK1A protein results in increased phosphorylation of MAPT protein] Harmine binds to DYRK1A protein Harmine results in decreased activity of DYRK1A protein
2-chloro-5-nitrobenzanilide inhibits the reaction [Harmine results in increased expression of UCP1 mRNA]; AZD 6244 inhibits the reaction [Harmine results in increased expression of UCP1 mRNA]; Harmine affects the reaction [Dietary Fats affects the expression of UCP1 mRNA]; Harmine inhibits the reaction [CHD4 protein affects the expression of UCP1 mRNA]; Harmine inhibits the reaction [CHD4 protein binds to UCP1 promoter]; N4-(9-ethyl-9H-carbazol-3-yl)-N2-(3-morpholin-4-ylpropyl)-pyrimidine-2,4-diamine inhibits the reaction [Harmine results in increased expression of UCP1 mRNA] Harmine results in increased expression of UCP1 mRNA; Harmine results in increased expression of UCP1 protein
Harmine inhibits the reaction [WNT3A protein results in decreased expression of ID2 mRNA]; Harmine inhibits the reaction [WNT3A protein results in increased expression of AXIN2 mRNA]
harmol results in decreased stability of CYP1A1 protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [harmol results in decreased stability of CYP1A1 protein]; harmol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; harmol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] harmol results in decreased activity of CYP1A1 protein
rutecarpine results in increased localization of AHR protein rutecarpine results in increased expression of AHR mRNA 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [rutecarpine results in increased localization of AHR protein]; AHR affects the reaction [rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein]; AHR affects the reaction [rutecarpine results in increased expression of CYP1A1 mRNA]; rutecarpine promotes the reaction [AHR protein binds to CYP1A1 promoter]; W 7 inhibits the reaction [rutecarpine results in increased localization of AHR protein] rutecarpine binds to AHR protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [rutecarpine binds to AHR protein]; rutecarpine inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; W 7 inhibits the reaction [rutecarpine binds to AHR protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; KN 93 inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [rutecarpine results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [rutecarpine results in increased expression of CYP1A1 mRNA]; AHR affects the reaction [rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein]; AHR affects the reaction [rutecarpine results in increased expression of CYP1A1 mRNA]; capsazepine inhibits the reaction [rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein]; capsazepine inhibits the reaction [rutecarpine results in increased expression of CYP1A1 mRNA]; rutecarpine promotes the reaction [AHR protein binds to CYP1A1 promoter]; rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein; W 7 inhibits the reaction [rutecarpine results in increased activity of and results in increased expression of CYP1A1 protein]; W 7 inhibits the reaction [rutecarpine results in increased expression of CYP1A1 mRNA] rutecarpine binds to CYP1A1 promoter 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [rutecarpine binds to CYP1A1 promoter]; W 7 inhibits the reaction [rutecarpine binds to CYP1A1 promoter]
rutecarpine promotes the reaction [CYP1A2 protein affects the metabolism of Theophylline] rutecarpine results in increased activity of CYP1A2 protein rutecarpine analog binds to and results in decreased activity of CYP1A2 protein; rutecarpine binds to and results in decreased activity of CYP1A2 protein
tubastatin A inhibits the reaction [[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate] results in increased expression of HDAC6 protein]; tubastatin A inhibits the reaction [bisphenol A results in increased expression of HDAC6 protein]
tubastatin A inhibits the reaction [[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate] results in increased expression of MYC protein]; tubastatin A inhibits the reaction [bisphenol A results in increased expression of MYC protein]
tubastatin A results in increased expression of PTEN mRNA [bisphenol A co-treated with tubastatin A] results in increased expression of PTEN mRNA; [mono-(2-ethylhexyl)phthalate co-treated with bisphenol A co-treated with tubastatin A] results in increased expression of PTEN mRNA; [mono-(2-ethylhexyl)phthalate co-treated with tubastatin A] results in increased expression of PTEN mRNA
browse the term
